2seventy Bio (TSVT) said late Monday that it has agreed to be acquired by Bristol Myers Squibb (BMY) for a price of $5 per share in an all-cash deal valuing the company at about $286 million.
The price represents an 88% premium over the March 7 closing price of $2.66 per share, the multiple myeloma-focused biotech company said.
2seventy bio said its board has unanimously recommended the deal to shareholders, some of which already agreed to tender their shares in support of the acquisition.
The transaction is expected to close in Q2, after which 2seventy bio's shares will no longer be listed for trading on Nasdaq, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.